Nektar Reports Q1 Revenue of $10.86M, Exceeding Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy NKTR?
Reports Q1 revenue $10.86M, consensus $10.69M. "2026 is shaping up to be a defining year for Nektar and for our lead biologic candidate rezpegaldesleukin," said Howard Robin, President and Chief Executive Officer of Nektar. "We have now shown that longer-term treatment with rezpegaldesleukin continues to deepen clinical responses in two distinct immune-mediated diseases, reinforcing our belief that this novel Treg mechanism can transform the treatment paradigm for autoimmune disease. The Phase 3 ZENITH-AD program in atopic dermatitis will initiate by July, and we will have our End-of-Phase 2 meeting for alopecia areata this quarter. With a substantially strengthened balance sheet and over one billion dollars in cash and investments, we are well positioned to advance rezpegaldesleukin into late-stage development with strong scientific and clinical conviction."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NKTR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NKTR
Wall Street analysts forecast NKTR stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 81.890
Low
102.00
Averages
123.43
High
165.00
Current: 81.890
Low
102.00
Averages
123.43
High
165.00
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nektar Therapeutics Q1 2026 Earnings Call Highlights
- Accelerated R&D Progress: Nektar plans to initiate the ZENITH-AD Phase III clinical trial for moderate to severe atopic dermatitis by July 2026, with the first data expected in mid-2028, thereby laying the groundwork for a BLA submission in 2029.
- Improved Financial Position: As of Q1 2026, Nektar reported cash and investments totaling $731.6 million, with expectations to increase to $800 million to $825 million by year-end 2026, demonstrating strong financing capabilities.
- R&D Expense Increase: R&D expenses are projected to rise quarterly in 2026, with Q1 expenditures at $35.7 million, reflecting ongoing investments in clinical trials that may impact future profitability.
- Management Transition: Current CFO Sandra Gardiner will retire on May 15, with Linda Rubinstein taking over, which could influence the company's strategic direction and execution capabilities.
See More
Nektar (NKTR) Q1 2026 Earnings Transcript
See More
Nektar Therapeutics Reports Q1 2026 Financial Results and Milestones
- Significant Cash Growth: As of March 31, 2026, Nektar's cash and marketable securities totaled $731.6 million, a substantial increase from $245.8 million on December 31, 2025, indicating a strengthened financial position that supports future R&D and clinical trials.
- Increased R&D Spending: The R&D expense for Q1 2026 was $35.7 million, up from $30.5 million in Q1 2025, primarily to support the Phase 3 clinical trial in atopic dermatitis, demonstrating the company's ongoing commitment to critical product development.
- Decreased Operating Costs: Total operating costs in Q1 2026 were $49.9 million, down from $55.0 million in Q1 2025, mainly due to reduced general and administrative expenses, which provides a solid foundation for cost control.
- Reduced Net Loss: The net loss for Q1 2026 was $44.9 million, or $1.82 per share, compared to a net loss of $50.9 million or $3.62 per share in Q1 2025, reflecting positive changes in the company's financial performance.
See More
Nektar Therapeutics Class Action Reminder
- Lawsuit Background: Nektar Therapeutics is facing a class action lawsuit due to the failure of its REZOLVE-AA trial results announced on December 16, 2025, which led to a 7.8% drop in stock price to $49.16 per share, resulting in investor losses.
- Trial Issues: The lawsuit alleges that Nektar did not follow applicable enrollment instructions and protocol standards in the REZOLVE-AA trial, which overstated the trial's overall integrity and prospects, adversely affecting investor decisions.
- Investor Rights: Affected investors must file a motion to be appointed as lead plaintiff in the class action by May 5, 2026, highlighting the importance of investor protection in the face of misleading corporate statements.
- Legal Consultation: Glancy Prongay Wolke & Rotter LLP offers legal consultation services, and investors can contact them via email or phone for more information to ensure their rights are protected.
See More
Class Action Filed Against Nektar Therapeutics for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Nektar Therapeutics, seeking damages for investors who purchased securities between February 26, 2025, and December 25, 2025, highlighting significant investor concerns regarding the company's compliance and operational transparency.
- Detailed Allegations: The complaint alleges that Nektar failed to adhere to applicable instructions and protocol standards in the REZOLVE-AA trial, which could significantly impact trial results, indicating serious management deficiencies in critical R&D projects that undermine investor confidence.
- Investor Rights Protection: Investors are encouraged to apply to be lead plaintiffs by May 5, 2026, demonstrating the legal team's commitment to safeguarding investor rights while reflecting uncertainty about the company's future prospects.
- Transparent Legal Fees: Bronstein, Gewirtz & Grossman, LLC states they will represent investors on a contingency fee basis, only charging fees upon successful recovery, thereby reducing the financial burden on investors and enhancing the appeal of participating in the lawsuit.
See More
Faruqi & Faruqi Investigates Nektar Investor Claims
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against Nektar Therapeutics, focusing on investors who purchased or acquired Nektar securities between February 26, 2025, and December 15, 2025, indicating possible legal risks for the company.
- Investor Rights Reminder: The firm reminds investors that May 5, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action against Nektar, emphasizing the importance of timely action to protect investor rights.
- Direct Contact Channels: Investors who suffered losses can contact Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options, providing a convenient consultation avenue.
- Potential Impact Assessment: This investigation may negatively affect Nektar's stock price and corporate reputation, prompting investors to monitor developments closely to assess their investment risks.
See More
Nektar Therapeutics Q1 2026 Earnings Call Highlights
- Accelerated R&D Progress: Nektar plans to initiate the ZENITH-AD Phase III clinical trial for moderate to severe atopic dermatitis by July 2026, with the first data expected in mid-2028, thereby laying the groundwork for a BLA submission in 2029.
- Improved Financial Position: As of Q1 2026, Nektar reported cash and investments totaling $731.6 million, with expectations to increase to $800 million to $825 million by year-end 2026, demonstrating strong financing capabilities.
- R&D Expense Increase: R&D expenses are projected to rise quarterly in 2026, with Q1 expenditures at $35.7 million, reflecting ongoing investments in clinical trials that may impact future profitability.
- Management Transition: Current CFO Sandra Gardiner will retire on May 15, with Linda Rubinstein taking over, which could influence the company's strategic direction and execution capabilities.
See More
Nektar (NKTR) Q1 2026 Earnings Transcript
See More
Nektar Therapeutics Reports Q1 2026 Financial Results and Milestones
- Significant Cash Growth: As of March 31, 2026, Nektar's cash and marketable securities totaled $731.6 million, a substantial increase from $245.8 million on December 31, 2025, indicating a strengthened financial position that supports future R&D and clinical trials.
- Increased R&D Spending: The R&D expense for Q1 2026 was $35.7 million, up from $30.5 million in Q1 2025, primarily to support the Phase 3 clinical trial in atopic dermatitis, demonstrating the company's ongoing commitment to critical product development.
- Decreased Operating Costs: Total operating costs in Q1 2026 were $49.9 million, down from $55.0 million in Q1 2025, mainly due to reduced general and administrative expenses, which provides a solid foundation for cost control.
- Reduced Net Loss: The net loss for Q1 2026 was $44.9 million, or $1.82 per share, compared to a net loss of $50.9 million or $3.62 per share in Q1 2025, reflecting positive changes in the company's financial performance.
See More
Nektar Therapeutics Class Action Reminder
- Lawsuit Background: Nektar Therapeutics is facing a class action lawsuit due to the failure of its REZOLVE-AA trial results announced on December 16, 2025, which led to a 7.8% drop in stock price to $49.16 per share, resulting in investor losses.
- Trial Issues: The lawsuit alleges that Nektar did not follow applicable enrollment instructions and protocol standards in the REZOLVE-AA trial, which overstated the trial's overall integrity and prospects, adversely affecting investor decisions.
- Investor Rights: Affected investors must file a motion to be appointed as lead plaintiff in the class action by May 5, 2026, highlighting the importance of investor protection in the face of misleading corporate statements.
- Legal Consultation: Glancy Prongay Wolke & Rotter LLP offers legal consultation services, and investors can contact them via email or phone for more information to ensure their rights are protected.
See More
Class Action Filed Against Nektar Therapeutics for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Nektar Therapeutics, seeking damages for investors who purchased securities between February 26, 2025, and December 25, 2025, highlighting significant investor concerns regarding the company's compliance and operational transparency.
- Detailed Allegations: The complaint alleges that Nektar failed to adhere to applicable instructions and protocol standards in the REZOLVE-AA trial, which could significantly impact trial results, indicating serious management deficiencies in critical R&D projects that undermine investor confidence.
- Investor Rights Protection: Investors are encouraged to apply to be lead plaintiffs by May 5, 2026, demonstrating the legal team's commitment to safeguarding investor rights while reflecting uncertainty about the company's future prospects.
- Transparent Legal Fees: Bronstein, Gewirtz & Grossman, LLC states they will represent investors on a contingency fee basis, only charging fees upon successful recovery, thereby reducing the financial burden on investors and enhancing the appeal of participating in the lawsuit.
See More
Faruqi & Faruqi Investigates Nektar Investor Claims
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against Nektar Therapeutics, focusing on investors who purchased or acquired Nektar securities between February 26, 2025, and December 15, 2025, indicating possible legal risks for the company.
- Investor Rights Reminder: The firm reminds investors that May 5, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action against Nektar, emphasizing the importance of timely action to protect investor rights.
- Direct Contact Channels: Investors who suffered losses can contact Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options, providing a convenient consultation avenue.
- Potential Impact Assessment: This investigation may negatively affect Nektar's stock price and corporate reputation, prompting investors to monitor developments closely to assess their investment risks.
See More
